COST EFFECTIVENESS OF DIFFERENT TARGETED TREATMENT SEQUENCES FOR HER2-POSITIVE METASTATIC BREAST CANCER

被引：0
|
作者：
Diaby, V [1 ]
Adunlin, G. [2 ]
Ali, A. [1 ]
Zeichner, S. [3 ]
Lopes, G. [4 ]
Kohn, C. G. [5 ]
Montero, A. J. [6 ]
机构：
[1] Florida A&M Univ, Tallahassee, FL 32307 USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Hosp Coracao & Oncoclin Brasil Grp, Sao Paulo, Brazil
[5] Univ St Joseph, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1592
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN93
引用
收藏
页码：A150 / A150
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [22] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [23] Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
    Sachdev, Jasgit C.
    Jahanzeb, Mohammad
    CLINICAL BREAST CANCER, 2012, 12 (01) : 19 - 29
  • [24] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
  • [25] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [26] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [27] HER2DX: Advances in targeted treatment of HER2-positive breast cancer
    Andujar, Juan M. Cejalvo
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2024, 37 (03):
  • [28] The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
    Antonazzo, Ippazio Cosimo
    Cortesi, Paolo Angelo
    Sopo, Gerardo Miceli
    Mazzaglia, Giampiero
    Conte, Pierfranco
    Mantovani, Lorenzo Giovanni
    CANCERS, 2023, 15 (04)
  • [29] COST-UTILITY ANALYSIS OF TRASTUZUMAB IN TREATMENT OF METASTATIC HER2-POSITIVE BREAST CANCER IN VIETNAM
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    VALUE IN HEALTH, 2014, 17 (07) : A643 - A643
  • [30] Treatment of HER2-positive breast cancer
    Figueroa-Magalhaes, Maria Cristina
    Jelovac, Danijela
    Connolly, Roisin M.
    Wolff, Antonio C.
    BREAST, 2014, 23 (02): : 128 - 136
12345